Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Urology / Nephrology News

Fourth International Consultation On Incontinence (ICI) - Drug Treatment Committee Highlights

Main Category: Urology / Nephrology
Also Included In: Pharmacy / Pharmacist
Article Date: 24 Jul 2008 - 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Karl-Erik Andersson, MD, PhD, and Christopher Chapple, MD, Committee Chairs

PARIS, FRANCE (UroToday.com) - Dr. Andersson began this presentation with a brief overview of the updated 2002 ICS definitions regarding lower urinary tract function and OAB and proposed theories for the pathophysiology of OAB. He described the paradigm shift that has taken place over the last several years with respect to the recognition of the important, even dominant role of the urothelium and afferent activity in the generation of OAB.

With respect to anticholingergic therapy, Dr. Andersson reviewed the structure of the urothelium/suburothelium and the interplay with afferent C-fibers and Adelta fibers. He showed a study demonstrating that oxybutynin dramatically decreases afferent activity. Anticholingergics are active during the filling phase and may block receptor activation from acetylcholine that has "leaked" from the urothelium because of stretching or from damaged cholinergic nerves. This inhibition of afferent activity occurs at much lower concentrations of drug than is required for inhibition of voiding activity, yielding a "therapeutic window" for OAB pharmacotherapy. This is a possible explanation for why the newer studies of anticholinergic use in male "BPH" patients generally do not show an increased risk of urinary retention or elevated post-void residuals with anticholinergic therapy. Including information from the last consultation, the committee identified 73 trials for inclusion in a meta-analysis. All five commercially marketed anticholinergic treatments attained Level 1 evidence and Grade A recommendation for treatment (tolterodine, fesoterodine, darifenacin, solifenacin and trospium). Oxybutynin was included in the drugs with mixed effects and also achieved Level 1/Grade A status.

Several other notable drugs commonly used for UI were also mentioned. Imipramine has non-selective antimuscarinic activity, alpha-adrenergic activity, and effects on renal water absorption. The committee noted serious issues with the cardiac toxicity profile and recommended imipramine be used with caution (Level 3 Grade C). Duloxetine, like imipramine, does not have an FDA indication for incontinence but is useful for pharmacological treatment of UI (Level 2 Grade B).

Vasopressin/DDAVP was given a Grade B recommendation for treatment of nocturia and Grade C for treatment of OAB. Treatment of OAB with alpha 1 antagonists has Level 1 evidence but received only a Grade D recommendation due to lack of proven efficacy. There is Level 2 evidence with a Grade B recommendation for Beta 3 agonists and lower levels of evidence for Beta 2 agonists. Treatment of LUTS with phosphodiesterase type 5 inhibitors is an area of tremendous clinical interest recently and there are several new RCT's in this arena. The committee gave a Grade B recommendation with Level 1 evidence.

Next, Dr. Andersson addressed intravesical therapies for neurogenic DO, most of which have level 2 evidence. Botulinum toxin A was given a grade A recommendation. Capsaicin, Resiniferatoxin and Botulinum toxin B were all given Grade C recommendations. For use in non-neurogenic patients (idiopathic DO), Botulinum toxin A has Level 2 evidence with a Grade B recommendation by the committee. Estrogen for OAB has Level 2 evidence with a Grade C recommendation.

Addressing pharmacotherapy for stress incontinence, Dr. Andersson noted the only standout drug is duloxetine with Level 1 evidence and a Grade A recommendation; the drug does not have an indication for SUI in the U.S., and the committee is concerned with the efficacy to adverse events ratio. Imipramine has Level 3 evidence and a Grade D, while estrogen also received a Grade D recommendation.

The committee pointed out that optimal dosing and pharmacokinetic interactions need further study. Dr. Andersson noted that the afferent system and higher centers will likely be areas of future investigation. One questioner asked what endpoints the committee chose to look at in evaluating drug treatments, as the primary endpoints differ greatly across studies. Dr. Chapple stated that the committee was aware of the challenges presented by this, and the committee attempted to gauge "overall efficacy" when evaluating the literature. There was also a question about using DDAVP in elderly patients who are more susceptible to the side effect of hyponatremia. The panel generally agreed that it is used in clinical practice but with caution.

Moderated by Christopher Chapple, MD, and Willie Davila, MD, at the Fourth International Consultation on Incontinence (ICI) - July 5 - 8, 2008. Palais des Congres, Paris, France.

Written by William Jaffe, MD, a Contributing Editor with UroToday.

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2008 - UroToday

View drug information on DDAVP.





Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Please fill in our survey

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
What Is Dialysis? What Is Kidney Dialysis?
07 Jun 2009
Dialysis is the artificial process of getting rid of waste (diffusion) and unwanted water (ultrafiltration) from the blood. This process is naturally done by our kidneys. Some people, however, may have failed or damaged...


Talking with Your Doctor image Talking with Your Doctor

Talking with your doctor can sometimes be difficult. Good health care, however, depends on an open dialogue between patients and doctors...

Talking with Your Doctor image Talking with Your Doctor

Talking with your doctor can sometimes be difficult. Good health care, however, depends on an open dialogue between patients and doctors...

View more videos...